Total Payments
$26,569
2024 Payments
$3,008
Companies
54
Transactions
1,304
Medicare Patients
2,297
Medicare Billing
$368,170
Payment Breakdown by Category
Food & Beverage$18,891 (71.1%)
Research$7,399 (27.8%)
Education$279.23 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,891 | 1,278 | 71.1% |
| Unspecified | $7,399 | 11 | 27.8% |
| Education | $279.23 | 15 | 1.1% |
Payments by Type
General
$19,170
1,293 transactions
Research
$7,399
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $5,347 | 18 | $0 (2019) |
| ABBVIE INC. | $3,333 | 208 | $0 (2024) |
| Amgen Inc. | $3,219 | 248 | $0 (2024) |
| PFIZER INC. | $2,587 | 219 | $0 (2024) |
| Eli Lilly and Company | $1,808 | 3 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $1,645 | 111 | $0 (2024) |
| UCB, Inc. | $1,577 | 92 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,310 | 63 | $0 (2024) |
| Lilly USA, LLC | $900.96 | 51 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $644.11 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,008 | 170 | ABBVIE INC. ($537.58) |
| 2023 | $2,832 | 161 | AbbVie Inc. ($558.17) |
| 2022 | $2,041 | 118 | ABBVIE INC. ($443.47) |
| 2021 | $1,289 | 71 | Amgen Inc. ($449.33) |
| 2020 | $1,369 | 76 | Eli Lilly and Company ($275.52) |
| 2019 | $2,911 | 254 | PFIZER INC. ($595.41) |
| 2018 | $5,270 | 245 | Eli Lilly and Company ($1,532) |
| 2017 | $7,850 | 209 | Celgene Corporation ($5,182) |
All Payment Transactions
1,304 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.57 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $8.92 | General |
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $1.90 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $26.62 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $2.75 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $10.45 | General |
| 12/10/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $33.29 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Immunology | ||||||
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/20/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Analgesic | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $10.30 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $8.98 | General |
| 11/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Immunology | ||||||
| 11/08/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $32.59 | General |
| Category: Immunology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Inflammation | ||||||
| 10/31/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.89 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-10004-AS-001 | Celgene Corporation | $4,976 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $1,560 | 2 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $614.25 | 7 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $247.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 502 | 1,177 | $306,936 | $85,291 |
| 2022 | 6 | 497 | 1,088 | $303,079 | $82,629 |
| 2021 | 7 | 587 | 1,291 | $358,802 | $100,922 |
| 2020 | 11 | 711 | 2,260 | $342,440 | $99,327 |
Total Patients
2,297
Total Services
5,816
Medicare Billing
$368,170
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 265 | 776 | $241,220 | $66,833 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 116 | 177 | $39,052 | $10,248 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $15,926 | $4,948 | 31.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 31 | 56 | $8,960 | $2,704 | 30.2% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 27 | 53 | $795.00 | $301.07 | 37.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 22 | $770.00 | $218.00 | 28.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 54 | $213.43 | $39.03 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 261 | 739 | $236,480 | $65,215 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 128 | 191 | $43,357 | $10,688 | 24.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $15,192 | $4,269 | 28.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 28 | 38 | $6,270 | $1,937 | 30.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 27 | 58 | $870.00 | $274.65 | 31.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 26 | $910.00 | $245.99 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 274 | 777 | $248,994 | $71,473 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 177 | 330 | $73,680 | $19,073 | 25.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 56 | 56 | $23,660 | $6,678 | 28.2% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 28 | 53 | $8,692 | $2,733 | 31.4% |
| 20600 | Aspiration and/or injection of small joint or joint capsule | Office | 2021 | 16 | 19 | $2,496 | $612.04 | 24.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 15 | 22 | $770.00 | $223.60 | 29.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 21 | 34 | $510.00 | $127.89 | 25.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 263 | 679 | $185,367 | $50,297 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 231 | 425 | $79,900 | $22,052 | 27.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 11 | 900 | $34,200 | $14,091 | 41.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 64 | 64 | $26,624 | $7,613 | 28.6% |
| 20600 | Aspiration and/or injection of small joint or joint capsule | Office | 2020 | 33 | 54 | $7,085 | $1,949 | 27.5% |
About Dr. Michael Burnette, MD
Dr. Michael Burnette, MD is a Rheumatology healthcare provider based in Valrico, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154433100.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Burnette, MD has received a total of $26,569 in payments from pharmaceutical and medical device companies, with $3,008 received in 2024. These payments were reported across 1,304 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($18,891).
As a Medicare-enrolled provider, Burnette has provided services to 2,297 Medicare beneficiaries, totaling 5,816 services with total Medicare billing of $368,170. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Internal Medicine
- Location Valrico, FL
- Active Since 08/31/2006
- Last Updated 03/04/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1154433100
Products in Payments
- Otezla (Drug) $5,279
- Enbrel (Biological) $2,430
- XELJANZ (Drug) $2,263
- Cimzia (Drug) $1,441
- RINVOQ (Biological) $1,413
- BENLYSTA (Biological) $1,279
- COSENTYX (Biological) $1,217
- Humira (Biological) $1,144
- TALTZ (Drug) $739.56
- ORENCIA (Biological) $644.11
- Tymlos (Biological) $497.64
- SAPHNELO (Biological) $496.56
- SKYRIZI (Biological) $397.55
- TREMFYA (Drug) $396.21
- COSENTYX (Drug) $379.35
- KEVZARA (Drug) $310.33
- Rituxan (Biological) $284.87
- ACTHAR (Biological) $168.94
- EVENITY (Biological) $163.00
- LYRICA (Drug) $162.77
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.